The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 266-273

  Aguzzi, Maria S ^a   Faraone, Debora ^a   D'Arcangelo, Daniela ^a   De Marchis, Francesco ^a   Toietta, Gabriele ^a   Ribatti, Domenico ^b   Parazzoli, Alberto ^c   Colombo, Paolo ^c   Capogrossi, Maurizio C ^a   Facchiano, Antonio ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b Dipartimento Anatomia Umana   (Italy)

^c Accelera Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 DERIVED PEPTIDE FREG; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; GENE INTERACTION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; TOXICITY TESTING;

ANIMALIA;

EID: 79551621176     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.211     Document Type: Article

References (41)

1. Garbe, C, Peris, K, Hauschild, A, Saiag, P, Middleton, M, Spatz, A et al. (2010). Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46: 270-283.
2. Gandini, S, Sera, F, Cattaruzza, MS, Pasquini, P, Abeni, D, Boyle, P et al. (2005). Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41: 28-44. (Pubitemid 40029657)
3. Zhang, D, Ouyang, J, Wang, N, Zhang, Y, Bie, J and Zhang, Y (2009). Promotion of PDGF-induced endothelial cell migration by phosphorylated VASP depends on PKA anchoring via AKAP. Mol Cell Biochem 335: 1-11.
4. Faraone, D, Aguzzi, MS, Toietta, G, Facchiano, AM, Facchiano, F, Magenta, A et al. (2009). Platelet-derived growth factor-receptor strongly inhibits melanoma growth in vitro and in vivo. Neoplasia 11: 732-742.
5. Hoch, RV and Soriano, P (2003). Roles of PDGF in animal development. Development 130: 4769-4784.
6. Long, JS, Yokoyama, K, Tigyi, G, Pyne, NJ and Pyne, S (2006). Lipid phosphate phosphatase-1 regulates lysophosphatidic acid- and platelet-derived-growth-factorinduced cell migration. Biochem J 394(Pt 2): 495-500.
7. Heldin, CH and Westermark, B (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
8. Heldin, CH, Ostman, A and Rönnstrand, L (1998). Signal transduction via plateletderived growth factor receptors. Biochim Biophys Acta 1378: F79-113.
9. Andrae, J, Gallini, R and Betsholtz, C (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
10. Ornitz, DM and Itoh, N (2001). Fibroblast growth factors. Genome Biol 2: REVIEWS3005.
11. Sperinde, GV and Nugent, MA (2000). Mechanisms of fibroblast growth factor 2 intracellular processing: a kinetic analysis of the role of heparan sulfate proteoglycans. Biochemistry 39: 3788-3796.
12. Beenken, A and Mohammadi, M (2009). The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
13. Barillari, G, Sgadari, C, Fiorelli, V, Samaniego, F, Colombini, S, Manzari, V et al. (1999). The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the ?5?1 and ?v?3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94: 663-672.
14. Wang, H, Rubin, M, Fenig, E, DeBlasio, A, Mendelsohn, J, Yahalom, J et al. (1997). Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 57: 1750-1757.
15. Chandler, LA, Sosnowski, BA, Greenlees, L, Aukerman, SL, Baird, A and Pierce, GF (1999). Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer 81: 451-458.
16. Carmeliet, P (2000). Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? Circ Res 87: 176-178.
17. Jensen, P, Pedersen, EG, Zimmer, J, Widmer, HR and Meyer, M (2008). Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease. Brain Res 1218: 13-20.
18. Bellucci, C, Lilli, C, Baroni, T, Parnetti, L, Sorbi, S, Emiliani, C et al. (2007). Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med 13: 542-550.
19. Nagao, S, Murao, K, Imachi, H, Cao, WM, Yu, X, Li, J et al. (2006). Platelet derived growth factor regulates ABCA1 expression in vascular smooth muscle cells. FEBS Lett 580: 4371-4376.
20. Chen, PY, Simons, M and Friesel, R (2009). FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor ?-mediated regulation of vascular smooth muscle marker gene expression. J Biol Chem 284: 15980-15992.
21. Wang, Z, Kong, D, Li, Y and Sarkar, FH (2009). PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets 10: 38-41.
22. Schwertfeger, KL (2009). Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 10: 632-644.
23. Facchiano, A, De Marchis, F, Turchetti, E, Facchiano, F, Guglielmi, M, Denaro, A et al. (2000). The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci 113 (Pt 16): 2855-2863.
24. De Marchis, F, Ribatti, D, Giampietri, C, Lentini, A, Faraone, D, Scoccianti, M et al. (2002). Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its receptor. Blood 99: 2045-2053.
25. Russo, K, Ragone, R, Facchiano, AM, Capogrossi, MC and Facchiano, A (2002). Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity. J Biol Chem 277: 1284-1291.
26. Faraone, D, Aguzzi, MS, Ragone, G, Russo, K, Capogrossi, MC and Facchiano, A (2006). Heterodimerization of FGF-receptor 1 and PDGF-receptor: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 107: 1896-1902.
27. Palumbo, R, Gaetano, C, Antonini, A, Pompilio, G, Bracco, E, Rönnstrand, L et al. (2002). Different effects of high and low shear stress on platelet-derived growth factor isoform release by endothelial cells: consequences for smooth muscle cell migration. Arterioscler Thromb Vasc Biol 22: 405-411.
28. Koyama, N, Hart, CE and Clowes, AW (1994). Different functions of the plateletderived growth factor and receptors for the migration and proliferation of cultured baboon smooth muscle cells. Circ Res 75: 682-691.
29. Heldin, CH (1997). Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 410: 17-21.
30. Facchiano, A, Russo, K, Facchiano, AM, De Marchis, F, Facchiano, F, Ribatti, D et al. (2003). Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem 278: 8751-8760.
31. Levin, EG, Sikora, L, Ding, L, Rao, SP and Sriramarao, P (2004). Suppression of tumor growth and angiogenesis in vivo by a truncated form of 24-kd fibroblast growth factor (FGF)-2. Am J Pathol 164: 1183-1190.
32. Meddahi, A, Lemdjabar, H, Caruelle, JP, Barritault, D and Hornebeck, W (1995). Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 77: 703-706.
33. Grieb, TA and Burgess, WH (2000). The mitogenic activity of fibroblast growth factor-1 correlates with its internalization and limited proteolytic processing. J Cell Physiol 184: 171-182.
34. Hanada, K, Yewdell, JW and Yang, JC (2004). Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427: 252-256.
35. Totta, P, De Cristofaro, R, Giampietri, C, Aguzzi, MS, Faraone, D, Capogrossi, MC et al. (2009). Thrombin-mediated impairment of fibroblast growth factor-2 activity. FEBS J 276: 3277-3289.
36. Strieth, S, Eichhorn, ME, Sutter, A, Jonczyk, A, Berghaus, A and Dellian, M (2006). Antiangiogenic combination tumor therapy blocking ?(v)-integrins and VEGFreceptor- 2 increases therapeutic effects in vivo. Int J Cancer 119: 423-431.
37. Gao, YJ, Cheng, JK, Zeng, Q, Xu, ZZ, Decosterd, I, Xu, X et al. (2009). Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol 219: 146-155.
38. Anderberg, C, Li, H, Fredriksson, L, Andrae, J, Betsholtz, C, Li, X et al. (2009). Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 69: 369-378.
39. Ogawa, Y, Kawamura, T, Furuhashi, M, Tsukamoto, K and Shimada, S (2008). Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci 51: 190-199.
40. Aguzzi, MS, Giampietri, C, De Marchis, F, Padula, F, Gaeta, R, Ragone, G et al. (2004). RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells. Blood 103: 4180-4187.
41. Was, H, Cichon, T, Smolarczyk, R, Rudnicka, D, Stopa, M, Chevalier, C et al. (2006). Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 169: 2181-2198.